New pill shows promise for common lung cancer mutation
NCT ID NCT05463224
First seen Jan 08, 2026 · Last updated Apr 28, 2026 · Updated 19 times
Summary
This study tests a daily pill called lazertinib in 150 people with advanced non-small cell lung cancer that has specific EGFR mutations. Participants have not had prior targeted therapy. The goal is to see how well the drug controls the cancer and to understand why resistance may develop. This is a phase 2 trial, meaning it checks both effectiveness and safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Samsung Medical Center
Seoul, Gangnamgu, 06351, South Korea
Conditions
Explore the condition pages connected to this study.